Funding for the AIDS Drug Assistance Program (ADAP) has lagged behind the number of persons needing antiretroviral therapy, leading to waiting lists and reduction of needed treatments and services. This paper demonstrates a method of providing more treatment for the same amount of money by selecting clinically equivalent, but lower-cost drug regimens. Average wholesale prices (AWPs) were used to calculate the annual costs of preferred, alternative, and acceptable regimens. The cost of each regimen was divided into $1,000,000 to determine how many patients could be treated per $1,000,000 that an ADAP had to spend. AWPs for preferred regimens ranged from $25,318 to 35,645 per year. For alternative regimens, the range of annual AWPs was $22,002Á$32,335. The range for the acceptable regimens was $19,031Á$31,543. The range of person treated per $1,000,000 per year was from 28 to 52. Funding shortages will lead ADAPs to resort to waiting lists or other means of denying appropriate care unless alternative approaches to treatment are sought. Cost conscious selection of regimens where there is no harm to individual patients is one alternative approach. Medical conditions that allow exceptions to lower-cost-based regimens must be developed with the assistance of clinicians.
Introduction
The US government is a major provider of antiretroviral therapy (ART) to HIV-infected individuals. As much as 226,419 persons were receiving services or medications through the AIDS Drug Assistance Program (ADAP) in March 2012 including 32,522 clients who were newly enrolled in 2011Á2012 (National Alliance of State and Territorial AIDS Directors, 2012a). The April 2012 appropriation for ADAP was $900 million, an increase of $15 million from 2011. Because of increased demand for ADAP services, the funding was supplemented by $69 million. The supplement eliminated most of the waiting lists for patients who were eligible ART but lived in states where all available ADAP funds were exhausted (National Alliance of State and Territorial AIDS Directors, 2012b). Waiting lists had reached 9298 persons in September 2011. The waiting lists have been reduced to 58 persons in December 2012 through either the additional funds or changing eligibility requirements (National Alliance of State and Territorial AIDS Directors, 2012c).
The funding crisis is quite likely to reoccur in future years. Increases in new clients each year will require more funding. However, it does not seem likely additional funds will be forthcoming. The US Senate committee recommended an appropriation of $963.3 million while the House of Representatives has not yet acted. The Senate committee's recommendation increased last year's original appropriation but is less than the supplemented 2012 ADAP budget. The current congressional climate seems more concerned about expenditure reduction rather than the program expansion. Other funding sources are unlikely. ADAP is administered by the states and has been supplemented by state appropriations in 37 states. State funding amounted to 16% of total ADAP funding in 2011, a decline from 21% in 2009 (Kaiser Family Foundation, 2012 Kaiser Family Foundation Fact Sheet, 2009 ). States are unlikely to provide additional funds because they are faced with fiscal crises and have reduced their HIV expenditures by $170,000,000 in 2009 alone (Centers for Disease Control and Prevention, 2010) .
When faced with shortfalls in available funds, policy-makers have to deal with the simple formula: The other approach to dealing with funding shortages would be to find ways for getting the same clinical impact for less money. This could be done by comparing costs of drug regimens that are considered clinically equivalent and determining if additional persons could be treated by using lower-cost regimens. This paper examines potential cost reductions that could be achieved by utilizing either a less expensive regimens.
Methods
The Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents classifies various combinations of drugs as appropriate therapies for the initial treatment of HIV infection in adults and adolescents. These are classified into three categories: (1) preferred regimens, (2) acceptable regimens, and (3) alternative regimens. Drug combinations are put in these categories based on the strength of the science that determines the regimen's effectiveness and the potential disadvantages associated with its use (Department of Health and Human Services, 2012a).
This paper assumes that any regimen in one of these categories is clinically equivalent to others in the category. Therefore, a lower-cost regimen is a more preferable combination unless there are contraindications for its use in an individual patient. The cost of a regimen is idiosyncratic to the particular purchaser of the medications. Good negotiators or large volumes purchasers will usually pay less for medications. The authors of this paper recognize that different prices will be paid by different purchasers and are merely showing a method by which costs of regimens can be compared. In addition, the paper will show how different regimens will be able to treat different numbers of patients. It will do this by determining how many persons could be treated per year with every regimen for each $1,000,000 that a payer (e.g., a state ADAP) might have to spend. This will be done by dividing $1,000,000 by the annual cost for each regimen.
The prices for each of the drugs were derived from the ''average wholesale prices (AWPs) that were published in the 27 March 2012 Guidelines (Department of Health and Human Services, 2012b). Coformulated combination AWPs were used for abacavir/lamivudine (Epzicom † ), tenofovir/emtricitabine (Truvada † ), zidovudine/lamivudine (Combivir † ), lopinavir/ ritonavir (Kaletra † ), rilpivirine/tenofovir/emtricitabine (Complera † ), and efavirenz/tenofovir/emtricitabine (Atripla † ). The daily cost for all of the drugs at their recommended doses in a regimen was then multiplied by 365 to determine the annual cost. Table 1 shows the annual AWP costs of the panel's four preferred regimens for initial treatment of HIV infection. The combination based on efavirenz, tenofovir, and emtricitabine had the lowest AWP at $25,318 per year while combinations including either atazanavir/ritonavir or darunavir/ritonavir together with coformulated tenofovir and emtricitabine had Persons treated per year per $1,000,000 range from 30 to 45. The regimen containing efavirenz with coformulated abacavir and lamivudine has the lowest annual cost, while the regimen including darunavir/ ritonavir and coformulated abacavir and lamivudine has the highest AWP.
Results
The AWP of acceptable regimens ranged from $19,031 to 31,543. The combination including extended release nevirapine with coformulated abacavir and lamivudine has the lowest annual cost of all evaluated regimens and is closely followed by the NNRTI-based regimen containing efavirenz and coformulated zidovudine and lamivudine. An ADAP program could provide drugs for up to 52 persons who were prescribed an acceptable NNRTI-based regimen for every $1,000,000 in its annual budget. The regimen containing atazanavir/ritonavir/abacavir/lamivudine would treat 31 persons per year.
Discussion
AWP is not the price that an ADAP will pay for a drug because of discounting. However, AWP provides a common benchmark against which all of the combinations could be compared. Purchasers of ART can adjust the calculations to reflect their prices for ART drugs. Some of these drugs are now available in generic form. These have AWPs that are 10Á37% lower than brand name medications (Department of Health and Human Services, 2012b). However, these ostensibly lower prices do not reflect the market where discounts or rebates may eliminate differences. This paper did not intend to find the lowest ART cost or to suggest that it should be the one that is prescribed by clinicians. No single regimen is the best combination for any particular patient. Side effects, concurrent conditions, resistance patterns, drug interactions, and patient preferences all play a role in determining which is the best regimen a given patient. However, when there is therapeutic indifference between regimens, cost should become an important consideration in a time of constrained resources. The potential savings can be seen by the fact that the AWP per year difference of $16,614 between the most expensive regimen ($35,645 per year) and the least expensive regimen ($19,031 per year). This suggests that 1.9 times as many patients could be treated using the lowest-cost regimen. Once similar cost calculations are done using local prices, ADAP administrators can ask for a justification for prescribing more expensive combinations. However, this should not be done lightly as great harm could be done without proper safeguards. These safeguards should follow rules that are developed by highly experienced HIV clinicians. These rules could lay out the exceptions to using less costly regimens. These are not bureaucratic decisions but rather clinical decisions that have life-threatening implications, and thus should be made by clinicians.
Conclusion
It seems likely that either patients will be denied access to ART or someone will make cost-based decisions to assure access. The latter would seem to be the best approach because it seems patently unfair to deny some HIV-infected individual's access to ART while others consume resources that do not provide them a clinical advantage over less expensive alternatives. If deciding to use lower-cost alternatives becomes the means for staying within a budget, it is hoped that the decisions will be based on science as well as costs. Expert panels who establish levels of preference for various regimens should consider costs when they evaluate regimens. Otherwise non-clinician administrators will make these decisions based only on cost without the knowledge of how their decisions may harm patients.
